• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境与卵巢癌细胞之间的表观遗传相互作用:一条鲜有人走的治疗途径。

Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.

作者信息

Klymenko Yuliya, Nephew Kenneth P

机构信息

Cell, Molecular and Cancer Biology Program, Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405, USA.

Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46617, USA.

出版信息

Cancers (Basel). 2018 Aug 30;10(9):295. doi: 10.3390/cancers10090295.

DOI:10.3390/cancers10090295
PMID:30200265
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6162502/
Abstract

Metastatic dissemination of epithelial ovarian cancer (EOC) predominantly occurs through direct cell shedding from the primary tumor into the intra-abdominal cavity that is filled with malignant ascitic effusions. Facilitated by the fluid flow, cells distribute throughout the cavity, broadly seed and invade through peritoneal lining, and resume secondary tumor growth in abdominal and pelvic organs. At all steps of this unique metastatic process, cancer cells exist within a multidimensional tumor microenvironment consisting of intraperitoneally residing cancer-reprogramed fibroblasts, adipose, immune, mesenchymal stem, mesothelial, and vascular cells that exert miscellaneous bioactive molecules into malignant ascites and contribute to EOC progression and metastasis via distinct molecular mechanisms and epigenetic dysregulation. This review outlines basic epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulators, and summarizes current knowledge on reciprocal interactions between each participant of the EOC cellular milieu and tumor cells in the context of aberrant epigenetic crosstalk. Promising research directions and potential therapeutic strategies that may encompass epigenetic tailoring as a component of complex EOC treatment are discussed.

摘要

上皮性卵巢癌(EOC)的转移扩散主要通过原发性肿瘤的细胞直接脱落进入充满恶性腹水的腹腔来实现。在液流的推动下,细胞在整个腹腔内分布,广泛播种并穿透腹膜内衬侵入,然后在腹部和盆腔器官中重新开始继发性肿瘤生长。在这个独特的转移过程的所有步骤中,癌细胞存在于一个多维肿瘤微环境中,该微环境由腹腔内驻留的癌症重编程成纤维细胞、脂肪细胞、免疫细胞、间充质干细胞、间皮细胞和血管细胞组成,这些细胞将多种生物活性分子释放到恶性腹水中,并通过不同的分子机制和表观遗传失调促进EOC的进展和转移。本综述概述了基本的表观遗传机制,包括DNA甲基化、组蛋白修饰、染色质重塑和非编码RNA调节因子,并总结了在异常表观遗传串扰的背景下,关于EOC细胞微环境中每个参与者与肿瘤细胞之间相互作用的当前知识。还讨论了可能将表观遗传调整作为复杂EOC治疗组成部分的有前景的研究方向和潜在治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/49611456d6eb/cancers-10-00295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/6ee9310a991f/cancers-10-00295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/16ab0e67d491/cancers-10-00295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/49611456d6eb/cancers-10-00295-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/6ee9310a991f/cancers-10-00295-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/16ab0e67d491/cancers-10-00295-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d97e/6162502/49611456d6eb/cancers-10-00295-g003.jpg

相似文献

1
Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.肿瘤微环境与卵巢癌细胞之间的表观遗传相互作用:一条鲜有人走的治疗途径。
Cancers (Basel). 2018 Aug 30;10(9):295. doi: 10.3390/cancers10090295.
2
The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.腔道转移生态系统与上皮性卵巢癌扩散
Front Endocrinol (Lausanne). 2022 Apr 28;13:886533. doi: 10.3389/fendo.2022.886533. eCollection 2022.
3
Exosomes from Human Omental Adipose-Derived Mesenchymal Stem Cells Secreted into Ascites Promote Peritoneal Metastasis of Epithelial Ovarian Cancer.人脐带来源脂肪间充质干细胞分泌的细胞外囊泡进入腹水促进上皮性卵巢癌腹膜转移。
Cells. 2022 Oct 27;11(21):3392. doi: 10.3390/cells11213392.
4
Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.间皮细胞与肿瘤细胞相互作用,以在腹腔积液中形成卵巢癌多细胞球体。
Clin Exp Metastasis. 2016 Dec;33(8):839-852. doi: 10.1007/s10585-016-9821-y. Epub 2016 Sep 9.
5
Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.单细胞测序恶性腹水揭示上皮性卵巢癌进展过程中肿瘤微环境的转录组重构。
Genes (Basel). 2022 Dec 2;13(12):2276. doi: 10.3390/genes13122276.
6
Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.卵巢癌上皮-间质表型可塑性的复杂决定因素
Cancers (Basel). 2017 Aug 9;9(8):104. doi: 10.3390/cancers9080104.
7
Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components.腹水助力卵巢癌细胞的转移之旅:各种细胞成分的协同作用。
Int J Mol Sci. 2022 Apr 15;23(8):4383. doi: 10.3390/ijms23084383.
8
Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment.卵巢癌微环境中的癌症-间皮细胞和癌症-巨噬细胞相互作用。
Am J Physiol Cell Physiol. 2023 Sep 1;325(3):C721-C730. doi: 10.1152/ajpcell.00461.2022. Epub 2023 Aug 7.
9
Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis.上皮性卵巢癌干细胞分化的表观基因组分析揭示了 GPD1 相关的免疫抑制微环境和不良预后。
Int J Mol Sci. 2022 May 4;23(9):5120. doi: 10.3390/ijms23095120.
10
The ascites N-glycome of epithelial ovarian cancer patients.上皮性卵巢癌患者的腹水N-糖组
J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001. Epub 2017 Feb 8.

引用本文的文献

1
Detecting vascular normalization in epithelial ovarian cancer.检测上皮性卵巢癌中的血管正常化。
Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.
2
Current data and future perspectives on DNA methylation in ovarian cancer (Review).当前关于卵巢癌中 DNA 甲基化的研究数据和未来展望(综述)。
Int J Oncol. 2024 Jun;64(6). doi: 10.3892/ijo.2024.5650. Epub 2024 May 17.
3
Effects of on growth and prognosis of glioma under hypoxia.缺氧条件下对胶质细胞瘤生长和预后的影响。

本文引用的文献

1
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.SWI/SNF 复合物在卵巢癌中的作用:机制见解与治疗意义。
Mol Cancer Res. 2018 Dec;16(12):1819-1825. doi: 10.1158/1541-7786.MCR-18-0368. Epub 2018 Jul 23.
2
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.靶向 EZH2 重塑肿瘤内调节性 T 细胞以增强癌症免疫。
Cell Rep. 2018 Jun 12;23(11):3262-3274. doi: 10.1016/j.celrep.2018.05.050.
3
Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Apr 28;48(4):499-507. doi: 10.11817/j.issn.1672-7347.2023.220396.
4
CXCL8 and the peritoneal metastasis of ovarian and gastric cancer.CXCL8 与卵巢癌和胃癌的腹膜转移。
Front Immunol. 2023 Jun 12;14:1159061. doi: 10.3389/fimmu.2023.1159061. eCollection 2023.
5
TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer.TIPE2 在卵巢上皮性癌中作为肿瘤抑制因子与肿瘤微环境免疫相关。
Aging (Albany NY). 2023 Feb 17;15(4):1052-1073. doi: 10.18632/aging.204529.
6
The multifaced role and therapeutic regulation of autophagy in ovarian cancer.自噬在卵巢癌中的多面作用及治疗调控
Clin Transl Oncol. 2023 May;25(5):1207-1217. doi: 10.1007/s12094-022-03045-w. Epub 2022 Dec 19.
7
Potential of histone deacetylase inhibitors for the therapy of ovarian cancer.组蛋白去乙酰化酶抑制剂治疗卵巢癌的潜力。
Front Oncol. 2022 Nov 25;12:1057186. doi: 10.3389/fonc.2022.1057186. eCollection 2022.
8
DNA repair as a shared hallmark in cancer and ageing.DNA 修复作为癌症和衰老的共同特征。
Mol Oncol. 2022 Sep;16(18):3352-3379. doi: 10.1002/1878-0261.13285. Epub 2022 Jul 28.
9
Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.卵巢癌中的癌症干细胞——肿瘤成功的根源和新型治疗的挑战性靶点。
Int J Mol Sci. 2022 Feb 24;23(5):2496. doi: 10.3390/ijms23052496.
10
Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects.细胞外囊泡作为癌症起始、药物治疗和疫苗前景中进展的调节剂的先驱作用。
Cells. 2022 Jan 31;11(3):490. doi: 10.3390/cells11030490.
表观遗传靶向脂肪细胞抑制高级别浆液性卵巢癌细胞的迁移和侵袭。
Mol Cancer Res. 2018 Aug;16(8):1226-1240. doi: 10.1158/1541-7786.MCR-17-0406. Epub 2018 May 14.
4
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.组蛋白甲基转移酶 EZH2:卵巢癌的治疗靶点。
Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437.
5
Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study.前列腺癌合并肥胖患者前列腺周围脂肪组织的全基因组 DNA 甲基化分析:一项初步研究。
Clin Epigenetics. 2018 Apr 17;10:54. doi: 10.1186/s13148-018-0490-3. eCollection 2018.
6
Human Glioblastoma-Derived Mesenchymal Stem Cell to Pericytes Transition and Angiogenic Capacity in Glioblastoma Microenvironment.人胶质母细胞瘤来源的间充质干细胞向周细胞的转变及在胶质母细胞瘤微环境中的血管生成能力
Cell Physiol Biochem. 2018;46(1):279-290. doi: 10.1159/000488429. Epub 2018 Mar 22.
7
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.重新利用泛组蛋白去乙酰化酶抑制剂治疗 ARID1A 突变型卵巢癌。
Cell Rep. 2018 Mar 27;22(13):3393-3400. doi: 10.1016/j.celrep.2018.03.019.
8
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.一项吉西他滨和顺铂治疗铂耐药复发性卵巢癌的 I 期临床试验:临床、药代动力学和药效学分析。
Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.
9
Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.5-氮杂胞苷治疗延缓神经胶质瘤异种移植物的生长:神经胶质瘤的一种潜在新治疗方法。
J Cancer Res Clin Oncol. 2018 May;144(5):809-819. doi: 10.1007/s00432-018-2600-1. Epub 2018 Feb 9.
10
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.